
AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes
pharmafile | August 30, 2018 | News story | Research and Development, Sales and Marketing | AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes
AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for the treatment of type 2 diabetes, an expansion of the existing authorisation for Bydureon.
This new formulation delivers via a once-weekly injection an improved single dose, requiring no titration and can be used alongside other glucose-lowering treatments such as basal insulin.
The EC’s decision was based on data derived from two clinical trials, wherein it reduced HbA1c levels by 1.4% after 28 weeks of use compared to Byetta (exenatide), another AZ therapy delivered twice-daily, which demonstrated reductions of just 1% in comparison. Additionally, Bydureon BCise reduced weight on average by 1.5kg as a monotherapy and 1.9kg when combined with oral antidiabetic medicines.
Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development at AstraZeneca,explained: “Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.”
Matt Fellows
Related Content

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

First 90 days of antipsychotic treatment linked to rapid metabolic changes
The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …





